ライフサイエンスコーパス: bone mineral density

1 after treatment started (including data for bone mineral density).

2 n associated with renal toxicity and reduced bone mineral density.

3 libido, vasomotor instability, and decreased bone mineral density.

4 ion, and then develop anemia and a decreased bone mineral density.

5 omy-induced osteoporosis results in improved bone mineral density.

6 exposure were independent predictors of low bone mineral density.

7 evious aromatase inhibitor use, and baseline bone mineral density.

8 n IBD patients and to IBD-associated loss of bone mineral density.

9 sumab, however, results in rapidly declining bone mineral density.

10 t or blunt the effects of corticosteroids on bone mineral density.

11 at individuals with RTS have decreased areal bone mineral density.

12 ents with osteoporosis/osteopenia and normal bone mineral density.

13 nflammatory bowel disease-associated loss of bone mineral density.

14 ceived placebo, had a significant decline in bone mineral density.

15 ea, but there were no such associations with bone mineral density.

16 sa that is independent of that provided with bone mineral density.

17 e surface, accompanied by a dramatic loss of bone mineral density.

18 ut not CD8+ T cells significantly diminished bone mineral density.

19 ears in a Women's Health Initiative study of bone mineral density.

20 95% CI -0.01, 0.01]; p = 0.80; n = 127,587); bone mineral density (0.01 g/cm(2) [95% CI -0.01, 0.03];

21 %, 95% CI 1.54 to 5.89; p=0.26), nor did hip bone mineral density (2.09%, 95% CI -1.45 to 5.63 vs 0.0

22 al women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the l

23 Bone mineral density, abdominal fat area, and paraspinal

24 ary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as

25 Bone mineral content (BMC) and areal bone mineral density (aBMD) were assessed by using dual-

26 are variables that are not captured by areal bone mineral density (aBMD), and dietary protein intakes

27 erum type I collagen C-telopeptide), low hip bone mineral density, absence of urticaria pigmentosa, a

28 Of six adults that were subjected to bone mineral density analysis, three presented with oste

29 eal (P=0.001) and volumetric (P<0.001-0.006) bone mineral density and 1.5- to 1.8-fold increases in r

30 Bone mineral density and abdominal fat and paraspinal mu

31 Alveolar bone mineral density and alveolar bone volume were quant

32 s, romosozumab was associated with increased bone mineral density and bone formation and with decreas

33 not dwarfed and had significantly increased bone mineral density and bone mineral content in femurs

34 ation and finite element analysis to measure bone mineral density and bone strength at the hip and sp

35 I) is a genetic disorder that results in low bone mineral density and brittle bones.

36 ning markers of bone turnover and whole-body bone mineral density and content were not affected by ei

37 Knockout (KO) (sost(-/-)) mice had increased bone mineral density and content, increased cortical and

38 f calcium supplements to prevent declines in bone mineral density and fractures is widespread in the

39 Hip and spine bone mineral density and glomerular filtration were each

40 Patients with type 1 diabetes have lower bone mineral density and higher risk of fractures.

41 g from autism have been reported to have low bone mineral density and increased risk for fracture, ye

42 genetic factors with pleiotropic effects on bone mineral density and lean mass.Bone mineral density

43 ffects on bone mineral density and lean mass.Bone mineral density and lean skeletal mass are heritabl

44 s is a bone disorder associated with loss of bone mineral density and micro architecture.

45 mine if computed tomographic (CT) metrics of bone mineral density and muscle mass can improve the pre

46 L5HU and PsoasL4-5, which are surrogates for bone mineral density and muscle mass, respectively, were

47 ignificantly higher bone volume/total volume bone mineral density and number of osteoblasts in the ra

48 nce were observed as were reduced whole body bone mineral density and reduced trabecular bone mass.

49 nce of viral suppression and led to improved bone mineral density and renal function.

50 In this population-based cohort study, bone mineral density and risk factors were used to calcu

51 istal radius was performed and evaluated for bone mineral density and trabecular and cortical bone mi

52 hese mice revealed a significant increase in bone mineral density and trabecular and cortical bone pa

53 CRB-15 also delayed loss of femur bone mineral density and trabecular microarchitecture.

54 ) levels and high bone turnover markers, low bone mineral density, and an increased risk of osteoporo

55 rception of health by a visual analog scale, bone mineral density, and body composition at baseline a

56 ice by adoptive transfer, and bone turnover, bone mineral density, and indices of bone structure and

57 Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the U.S. popul

58 in other frailty measures, body composition, bone mineral density, and physical functions.

59 Osteopenia, osteoporosis, and low bone mineral density are frequent in patients with HIV.

60 Most interventions used bone mineral density as a surrogate outcome, despite com

61 Consequently, bone mineral density assessment should be performed syst

62 We assessed the 96 week loss of bone mineral density associated with a nucleoside or nuc

63 ores of less than -2.0, mean change of spine bone mineral density at 2 years did not differ significa

64 of a CpG site proximal to the NFIX locus and bone mineral density at age 17.

65 mide had a significantly smaller decrease in bone mineral density at hip (mean change -0.10% [95% CI

66 ry end points included percentage changes in bone mineral density at other sites and in markers of bo

67 01), and a significantly smaller decrease in bone mineral density at spine (mean % change -1.30 vs -2

68 ry, ECSW was associated with preservation of bone mineral density at the central skeleton; however, i

69 t was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months.

70 ere associated with significant increases in bone mineral density at the lumbar spine, including an i

71 Bone mineral density at the spine, hip, and wrist were m

72 , vs. 55.0 to 52.3 kg [5% decrease]), as did bone mineral density at the total hip (grams per square

73 was also associated with large increases in bone mineral density at the total hip and femoral neck,

74 ciation between serum PFAS concentration and bone mineral density at total femur (TFBMD), femoral nec

75 entage changes in lumbar spine and total hip bone mineral density at week 48, assessed by dual energy

76 he safety endpoint of a 6% decrease in spine bone mineral density at week 72.

77 rnib monotherapy treatment reveal additional bone mineral density benefit but likely no added cardiov

78 Condylar bone mineral density (BMD) (computed tomography Hounsfie

79 l risedronate for prevention of reduction in bone mineral density (BMD) after 3 years of follow-up in

80 We investigated long-term changes in bone mineral density (BMD) among kidney transplant recip

81 ondition associated with progressive loss of bone mineral density (BMD) and compromised bone strength

82 Bone mineral density (BMD) and content (BMC) and body co

83 ody mass, shortened body length, and reduced bone mineral density (BMD) and content (BMC) first evide

84 c skeletal disorder characterized by reduced bone mineral density (BMD) and disrupted bone architectu

85 te the relationship of PD with osteoporosis, bone mineral density (BMD) and fracture risk.

86 ociation studies (GWASs) identified multiple bone mineral density (BMD) and fracture-associated loci.

87 hoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes po

88 have increased fracture risk, despite normal bone mineral density (BMD) and high BMI-factors that are

89 tary patterns that explain most variation in bone mineral density (BMD) and hip bone geometry are ass

90 tis C virus (HCV) is associated with reduced bone mineral density (BMD) and increased fracture rates,

91 g CAC progression, including measurements of bone mineral density (BMD) and novel bone markers in adu

92 Whether PM is associated with loss of bone mineral density (BMD) and risk of bone fractures is

93 Children with cancer may develop low bone mineral density (BMD) any time before or after diag

94 Bone mineral content (BMC) and bone mineral density (BMD) are positively correlated wit

95 ndependently predict fracture risk and, with bone mineral density (BMD) assessed by X-ray (DXA), may

96 was percentage change in lumbar spine areal bone mineral density (BMD) at 1 year.

97 one density contributing to lower volumetric bone mineral density (BMD) at both distal radius and tib

98 Bone mineral density (BMD) at the femoral neck, trochant

99 between clinical attachment level (CAL) and bone mineral density (BMD) at the lumbar spine and hip,

100 hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hi

101 e mineral content (BMC), bone area (BA), and bone mineral density (BMD) at the total body, lumbar spi

102 ng the relationship between dairy intake and bone mineral density (BMD) because they are unable to co

103 ce imaging in 215 healthy army recruits, and bone mineral density (BMD) by Dual X-Ray Absorptiometry

104 Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorpti

105 Bone mineral density (BMD) changes and fracture rate.

106 We compared adjusted bone mineral density (BMD) changes between human immunod

107 ave a protective effect on lumbar spine (LS) bone mineral density (BMD) compared with lower protein i

108 Bone mineral density (BMD) decreases 2%-6% in the 2 year

109 Little is known about bone mineral density (BMD) during pregnancy.

110 endpoint was percentage change in total hip bone mineral density (BMD) from baseline to week 48 in t

111 A high prevalence of low bone mineral density (BMD) has been reported among men w

112 Low bone mineral density (BMD) has been reported in many stu

113 an mass (ALM), quadriceps strength (QS), and bone mineral density (BMD) in 2986 men and women, aged 1

114 ed lumbar spine, total hip, and femoral neck bone mineral density (BMD) in 581 HIV-positive (94.7% re

115 identified more than 60 loci associated with bone mineral density (BMD) in adults but less is known a

116 leotide polymorphisms (SNPs) associated with bone mineral density (BMD) in adults.

117 Longitudinal data on bone mineral density (BMD) in HIV-infected children show

118 Initiation of TDF decreases bone mineral density (BMD) in HIV-infected people.

119 Weight loss (WL) negatively affects bone mineral density (BMD) in older populations and has

120 anion study to MA.27, we compared changes in bone mineral density (BMD) in the lumbar spine and total

121 o be significantly associated with decreased bone mineral density (BMD) in two independent cohorts in

122 in osteoprotegerin correlate with decreased bone mineral density (BMD) in untreated HIV infection.

123 monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal

124 Background: Bone mineral density (BMD) is a heritable phenotype that

125 Background: Whether change in bone mineral density (BMD) is an accurate indicator of a

126 High bone mineral density (BMD) is associated with an increas

127 Bone mineral density (BMD) is highly heritable, a major

128 Screening for osteoporosis with bone mineral density (BMD) is recommended for older adul

129 Several studies suggest that bone mineral density (BMD) is reduced in chronic inflamm

130 hrolithiasis, bone densitometry scoring, and bone mineral density (BMD) loss according to bone turnov

131 (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation.

132 [control (CON)].RCE significantly attenuated bone mineral density (BMD) loss at the L2-L4 lumbar spin

133 -analysis examining isoflavone therapies and bone mineral density (BMD) loss in peri- and postmenopau

134 Bone mineral density (BMD) measured by dual-energy x-ray

135 ted data on current anthropometric measures, bone mineral density (BMD) measured by dual-energy X-ray

136 Bone mineral density (BMD) of the lumbar spine and proxi

137 HNP) weight-loss diet caused greater loss in bone mineral density (BMD) over 24 mo.

138 Patient bone mineral density (BMD) predicts the likelihood of os

139 g-reported parental hip fracture in a unique bone mineral density (BMD) registry linked to administra

140 lowing strategies: no intervention; one-time bone mineral density (BMD) screening and selective bisph

141 Manitoba, Canada at the time of their first bone mineral density (BMD) test posttransplant (mean 1.1

142 lumbar spine bone mineral content (BMC) and bone mineral density (BMD) was assessed using DXA.

143 Trabecular bone mineral density (BMD) was determined in each verteb

144 Bone volume fraction (BVF) and bone mineral density (BMD) were assessed in hemimaxillae

145 nd whole-body bone mineral content (BMC) and bone mineral density (BMD) were measured at age 20 y thr

146 Plasma bone turnover markers and bone mineral density (BMD) were performed at weeks 0, 12

147 ion between protein intake with fracture and bone mineral density (BMD) within the Women's Health Ini

148 ated deficiencies and cardiovascular health, bone mineral density (BMD), and physical fitness.

149 ally relevant to osteoporosis, assessed from bone mineral density (BMD), as a new potential target of

150 content and density, cortical and trabecular bone mineral density (BMD), BMC, and bone area at the 4%

151 stigated their prospective associations with bone mineral density (BMD), bone area, and bone mineral

152 Offspring total body bone mineral density (BMD), bone mineral content (BMC),

153 ially vegan diets, are associated with lower bone mineral density (BMD), but this does not appear to

154 o, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in pat

155 ions aimed at preventing fracture, improving bone mineral density (BMD), or preventing or delaying os

156 tion between B-vitamin status biomarkers and bone mineral density (BMD), risk of osteoporosis, and bi

157 bl-Wnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly b

158 were accompanied by diminishing weight loss, bone mineral density (BMD), trabecular thickness, trabec

159 However, obese people have a higher bone mineral density (BMD), which suggests that low 25(O

160 ide association studies are also involved in bone mineral density (BMD).

161 nfection is associated with 2% to 6% loss of bone mineral density (BMD).

162 isease diagnosed primarily by measurement of bone mineral density (BMD).

163 useful tools to screen for reduced skeletal bone mineral density (BMD).

164 LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral density (BMD).

165 in low estrogen levels, which in turn affect bone mineral density (BMD).

166 actor for osteoporotic fractures and altered bone mineral density (BMD).

167 volume (BV), bone mineral content (BMC), and bone mineral density (BMD).

168 asing in children and is associated with low bone mineral density (BMD).

169 linically relevant, significant decreases in bone mineral density (BMD).

170 aviour and activity, response to therapy and bone mineral density (BMD).

171 (OD), bone vessel volume density (BVVD), and bone mineral density (BMD).

172 (LEA), menstrual disturbances, and decreased bone mineral density (BMD).

173 renteral nutrition (PN) may present with low bone mineral density (BMD).

174 protein, and parathyroid hormone as well as bone mineral density (BMD).

175 tiometry (DXA) was used for an assessment of bone mineral density (BMD).

176 ion, has also been associated with decreased bone mineral density (BMD).

177 e-wide association study summary datasets of bone mineral density (BMD).

178 elationship of those variables to changes in bone mineral density (BMD).

179 Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminat

180 Low bone-mineral density (BMD) is particularly concerning, b

181 dual-energy x-ray absorptiometry scans (low bone mineral density [BMD], 23.2%), serum ferritin (iron

182 DXA (reference standard) to determine areal bone mineral densities (BMDs), and (c) quantitative CT w

183 1 y of age and in a subgroup at 2 y of age : Bone mineral density, bone mineral content (BMC), area-a

184 p-null (Bsp(-/-)) mice exhibit reductions in bone mineral density, bone turnover, osteoclast activati

185 d a smaller decrease in lumbar spine and hip bone mineral density but greater accumulation of limb an

186 ) infection has been associated with reduced bone mineral density, but its association with fracture

187 tients with chronic hepatitis B have reduced bone mineral density, but the reduction is limited to 1

188 Compared with baseline, 12-month areal bone mineral density by DXA did not change significantly

189 micro-computed tomographic (CT) imaging and bone mineral density by peripheral quantitative CT scann

190 ect to their metabolic bone status including bone mineral density, calcium kinetics studies, and mark

191 In resource-limited settings, FRAX without bone mineral density can be substituted for DXA.

192 deletion of Cx37 (Cx37(-/-)) exhibit higher bone mineral density, cancellous bone volume, and mechan

193 absorptiometry (DEXA) was used to determine bone mineral density changes in TDF-exposed patients.

194 these antibodies led to a marked increase in bone mineral density, consistent with inhibition of oste

195 en switching from teriparatide to denosumab, bone mineral density continued to increase, whereas swit

196 nce of pathogenic variants in RECQL4 and low bone mineral density correlate with the history of incre

197 We also apply our approach to bone mineral density data, and again final models contai

198 There were no bone architectural or bone mineral density differences by microCT.

199 her fracture genetic risk score (Fx-GRS) and bone mineral density genetic risk score (BMD-GRS) modify

200 rong patient-level risk factors included low bone mineral density (hazard ratio [HR], 0.53 per unit i

201 nd was associated with a smaller decrease in bone mineral density; however, greater resistance and ga

202 ations in Col6a5 that underlies variation in bone mineral density in both mouse and human.

203 The effects of corticosteroids on bone mineral density in children seem to be more amenabl

204 ested a trend of less vertical bone gain and bone mineral density in controls (P >0.05).

205 ion of nutritional deficiencies and study of bone mineral density in high-risk patients.

206 t testosterone replacement therapy increases bone mineral density in hypogonadal men, including men w

207 sorptive agents are clearly able to preserve bone mineral density in men on ADT, whereas other approa

208 restores reproductive capacity and increases bone mineral density in patients with hypothalamic ameno

209 tch study, we aimed to assess the changes in bone mineral density in postmenopausal osteoporotic wome

210 At week 48, the mean percentage loss in bone mineral density in the lumbar spine was greater in

211 reater than -2.0 at baseline, mean change of bone mineral density in the spine at 2 years did not dif

212 n during flight, the greater the decrease in bone mineral density in the total hip (P = 0.031), troch

213 nes were significantly associated with spine bone mineral density, including BDNF, PDE4D, and SATB2,

214 48 months, the primary outcome of mean spine bone mineral density increased by 18.3% (95% CI 14.9-21.

215 Similarly, femoral neck bone mineral density increased more in the teriparatide

216 ineral density secondary outcomes, total hip bone mineral density increased more in the teriparatide

217 The rate of change of bone mineral density inferred from Ca isotopes is consis

218 ion Combined assessment of bone strength and bone mineral density is a cost-effective strategy for os

219 Systemic and persistent low bone mineral density is an independent prognostic factor

220 uce fragility fractures in patients with low bone mineral density is beyond the scope of the guidelin

221 ar growth attenuation and adverse effects on bone mineral density is generally low but should be cons

222 Bone mineral density is known to be a heritable, polygen

223 The pathogenesis of declining bone mineral density is poorly understood but it is inhe

224 years for altered BMB to produce changes in bone mineral density large enough to resolve by X-ray de

225 ovements in blood pressure, body mass index, bone mineral density, lipid levels, or quality-of-life m

226 s in eight loci, including seven established bone mineral density loci: WNT4, GALNT3, MEPE, CPED1/WNT

227 y, whereas ST-SPI diet only reduced cortical bone mineral density loss 3 wk post-OVX.

228 cant component of the pathophysiology of the bone mineral density loss associated with Inflammatory B

229 efficacy but with decreased renal injury and bone mineral density loss compared with TDF.

230 Bone mineral density loss has been described in TDF-trea

231 Total hip bone mineral density loss was similarly greater at week

232 Reduced bone mineral density, lower femoral bone mass, and alter

233 ctures in nontrauma patients at risk for low bone mineral density may go unreported at abdominal mult

234 osteoporotic fracture risk, with or without bone mineral density measurements obtained from dual-ene

235 splay skeletal alterations including reduced bone mineral density, modified bone structure and distin

236 ombined teriparatide and denosumab increased bone mineral density more than either drug alone.

237 Other than increased bone mineral density, no improvement rates exceeded thos

238 f fluoride's effects showed some increase in bone mineral density of adolescents and young adults in

239 Small reductions (<2%) in mean bone mineral density of hip and spine were detected by d

240 D status were demonstrated to reduce loss of bone mineral density on long-duration International Spac

241 s between groups in laboratory test results, bone mineral density, or body composition.

242 e percent change in posterior-anterior spine bone mineral density over 4 years.

243 Despite normal to high bone mineral density, patients with type 2 diabetes (T2D

244 e revealed increased remodelling and reduced bone mineral density portrayed by increased carbonate to

245 we show that Ppia(-/-) mice demonstrate low bone mineral density, reduced osteoblast numbers, and in

246 , and suppression of ectopic calcifications, bone mineral density reduction, pulmonary emphysema and

247 TDF-FTC prophylaxis, including the effect on bone mineral density, remains unknown.

248 8-year-old woman consults you after a recent bone mineral density screening revealed osteopenia, tota

249 For the bone mineral density secondary outcomes, total hip bone

250 users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vi

251 Lumbar spine bone mineral density showed a mean increase by day 85 an

252 revented the reduction in spinal and femoral bone mineral density, spinal bone volume/tissue volume,

253 ostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non

254 eplacement therapy has been shown to improve bone mineral density, studies have also linked bone loss

255 n increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibit

256 risk factors for osteoporotic fractures, and bone mineral density surveillance) originated from the q

257 commended in postmenopausal women who have a bone mineral density T score of -2.5 or less, a history

258 erate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1

259 The Mann-Whitney test was used to compare bone mineral density T scores and elastic moduli between

260 Her bone mineral density T scores are -2.6 at the lumbar spi

261 For bone mineral density T scores at the femoral neck, biome

262 eak relationships between elastic moduli and bone mineral density T scores in patients with fractures

263 lationship (R(2)) between elastic moduli and bone mineral density T scores was assessed.

264 .62 GPa; P = .01-.02), but no differences in bone mineral density T scores.

265 ient subgroups, including in patients with a bone mineral density T-score of -1 or higher at baseline

266 CI 0.31-0.64], p<0.0001) and in those with a bone mineral density T-score of less than -1 already at

267 y lean mass (TB-LM) and total-body less head bone mineral density (TBLH-BMD) regions in 10,414 childr

268 s associated with significantly less loss of bone mineral density than a standard regimen containing

269 urgery, the hind limb had significantly less bone mineral density than contralateral controls, confir

270 pids, and greater decreases from baseline in bone mineral density than did those who received placebo

271 ficantly smaller mean percentage declines in bone mineral density than those receiving tenofovir diso

272 hese mice displayed significant reduction in bone mineral density, trabecular bone volume, and cortic

273 ng bone disease that is characterised by low bone mineral density, typically assessed using dual-ener

274 ex, serum type I collagen C-telopeptide, hip bone mineral density, urticaria pigmentosa, and alcohol

275 anges in Ca isotope abundances to changes in bone mineral density using a simple model.

276 oncentration, serum phosphate concentration, bone mineral density, vascular calcification, renal func

277 with a significant increase in femoral neck bone mineral density; vascular calcification remained un

278 These groups exhibited decreased bone mineral density, volume fraction, and bone formatio

279 Bone mineral density was assessed in those patients with

280 Normal bone mineral density was detected in 2/8 case, osteopeni

281 Bone mineral density was determined by using dual-energy

282 Bone mineral density was expressed as Z scores (standard

283 Bone mineral density was higher and bone-turnover marker

284 Bone mineral density was measured at lumbar spine and th

285 Bone mineral density was measured at the lumbar spine an

286 Bone mineral density was measured at the lumbar spine an

287 DEXA for measuring bone mineral density was performed on every patient.

288 Concomitantly, alveolar bone mineral density was significantly lower in all thre

289 After 48 months, radius bone mineral density was unchanged in the teriparatide t

290 t mass, lean mass, bone mineral content, and bone mineral density, was determined by dual-energy X-ra

291 rial which tested the effect of denosumab on bone mineral density, we assessed the impact of this dru

292 Total and trabecular bone mineral density were significantly lower (-13.4% an

293 Texture parameters, but not bone mineral density, were associated with lowest lifeti

294 g/mL was significantly associated with lower bone mineral density, whereas an untransformed 25(OH)D c

295 the loss of total, trabecular, and cortical bone mineral density, whereas ST-SPI diet only reduced c

296 AS concentrations were associated with lower bone mineral density, which varied according to the spec

297 Thirty-seven patients had decreased bone mineral density with osteopenia in 24 patients and

298 usal associations between blood pressure and bone-mineral density with type 2 diabetes.

299 t model, there is a large loss of trabecular bone mineral density without apparent proportional chang

300 Mean bone mineral density z scores (lumbar spine and femur) r